When will generic Eliquis be available?
Generic versions of Eliquis (apixaban) are expected to become available after the drug’s patent and exclusivity protections expire. Eliquis is still under intellectual-property coverage, so a generic launch date depends on when those protections end and whether any challenges (or “skinny label”/ANDA litigation) clear the way.
What patent or exclusivity usually controls the generic date for Eliquis?
In the U.S., generic entry is typically tied to when the last relevant patent(s) covering the drug formulation, dosing regimen, or related methods expire, plus any granted exclusivity periods. Patent-expiry timelines can be complex because courts may delay launches even after an apparent expiry date, or manufacturers may settle litigation.
For a live, drug-specific view of Eliquis’s patent timeline and projected generic entry milestones, see DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/eliquis-apixaban/
Is “generic Eliquis” the same as a biosimilar?
No. Eliquis is a small-molecule oral anticoagulant (apixaban), so it would be pursued as a generic (an ANDA pathway in the U.S.), not as a biosimilar. The key question remains when generics can legally launch based on patent/exclusivity status.
What could delay or advance generic Eliquis availability?
Even if patents are near expiry, generic launch can be delayed by:
- ongoing patent litigation tied to ANDA filings,
- settlements that push launch dates,
- additional patents listed in the FDA Orange Book for Eliquis.
Those factors are why the most reliable answer comes from the most current patent-lifecycle tracking (like DrugPatentWatch.com), rather than a single calendar year estimate.
How can patients check the latest status?
Check:
- FDA’s Orange Book for “apixaban” entries (to see approved generics and what’s listed),
- the latest patent-expiry tracking updates for Eliquis (again, DrugPatentWatch.com is a common reference point).
Sources
- DrugPatentWatch.com – Eliquis (apixaban) patent and generic timeline